Jeff Collins to sit on a panel titled "Investing in Neurotech" at The Neurotech Industry Investing and Partnering Conference in Boston, MA

Genstruct and Sirtris Pharmaceuticals win Bio-IT World's Best Practices Award

 
CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better understand large scale biology, today announced that its joint collaboration with Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, has won Bio-IT World magazine’s 2008 Best Practices Award in the Drug Discovery & Development category. The project was focused on discovering mechanisms of action (MOA) for Type 2 diabetes.

Genstruct and Sirtris Pharmaceuticals win Bio-IT World's Best Practices Award

Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better understand large scale biology, today announced that its joint collaboration with Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, has won Bio-IT World magazine’s 2008 Best Practices Award in the Drug Discovery & Development category. The project was focused on discovering mechanisms of action (MOA) for Type 2 diabetes.

Bayhill Therapeutics presents data from a Phase 2 trial of BHT-3009 in multiple sclerosis at American Academy of Neurology 60th annual meeting

Bayhill Therapeutics, Inc. today announced that the Company’s co-founder and Vice President of Research, Hideki Garren, M.D., Ph.D., gave a podium presentation at the American Academy of Neurology 60th Annual Meeting (AAN) in Chicago. Dr. Garren’s presentation, “Results from a Phase II Trial of a Myelin Basic Protein Encoding DNA Vaccine for Relapsing Multiple Sclerosis," provides further analysis of data from a Phase II study evaluating BHT-3009, a tolerizing DNA vaccine for multiple sclerosis (MS).